



Draft Program

Friday, May 18th 2018

08.00–09.00 **Registration**

09.00–09.15 **Opening Ceremony** – Sally Marshall, President of EDNSG
Welcome - Erik Boddeke, Dean of Research Medical Sciences, UMCG

09.15–10.00 **Ruth Østerby Lecture** *Chair: Sally Marshall*
'Scar Wars': Fibrosis in diabetic kidney disease from pathogenesis to treatment
Richard Gilbert

10.00–11.00 **Session 1 - Novel biomarkers for predicting progression of diabetic kidney disease**
Chairs: Frederik Persson & Michelle Pena

- OP-1 Proteomic profile of circulating inflammatory proteins associated with 10-year risk of ESRD in T1 and T2 diabetes: Enrichment for TNF Receptor Superfamily members – **Niewczas M.**
- OP-2 A Bayesian approach for discovery of biomarkers of progression of nephropathy – **Colombo M.**
- OP-3 Systems Biology identified Molecular Pathways and Biomarkers Associated with Diabetic Kidney Disease progression – **Mulder S.**
- OP-4 Glomerular Hsp70 expression is reduced in patients with diabetic nephropathy whereas patients with increased Hsp70 plasma levels show no complications - **Zemva J.**

11.00–11.30 **Coffee and exhibition**

11.30–13.00 **Session 2 – Insights in diabetic kidney disease from experimental models**
Chairs: Luigi Gnudi & Richard Coward

- OP-5 Role of ABCA1 mediated mitochondrial dysfunction in podocyte injury and diabetic kidney disease – **Ducasa G. M.**
- OP-6 Neuropeptide Y is a novel modulator of podocyte function and its loss is protective in models of albuminuric renal disease – **Lay A. C.**
- OP-7 Myostatin: a new mediator of fibrosis in diabetic nephropathy? – **Picciotto D.**
- OP-8 Soluble Nogo-B overexpression inhibits diabetes-mediated endothelial cells proliferation in a murine model of early diabetic glomerulopathy – **Hernandez I.**
- OP-9 Endothelial heparan sulfate deficiency strongly reduces inflammation and fibrosis in murine diabetic nephropathy – **Van den Born J.**
- OP-10 Podocyte VEGF-A loss-of-function leads to diffuse glomerulosclerosis in diabetic and in eNOS knockout mice – **Tufro A.**



Draft Program

13.00–14.00 Lunch

14.00–14.45 Invited Lecture 1 *Chair: Carol Forsblom*
Novel biomarkers for disease & clinical trial application in DKD: Focus on precision medicine
Chirag Parikh

14.45–15.45 Poster Sessions and Exhibition

Parallel Poster Session 1 – From biomarkers to clinical trials in clinical setting

Chair: Richard Gilbert

- PP- 1 Higher collagen VI formation is associated with all-cause mortality in type 2 diabetic patients with microalbuminuria – **Hansen T. W.**
- PP-2 Association of circulating Galectin3 and estimated Glomerular Filtration Rate in type 2 diabetes. – **Barrios C.**
- PP-3 Higher Intraindividual HDL-Cholesterol and triglyceride variability are associated with the development and progression of diabetic nephropathy in individuals with type 1 Diabetes – **Jansson F. J.**
- PP-4 Cardio-renal prognosis by residual proteinuria level in diabetic CKD under nephrology care – **Provenzano M.**
- PP-5 Effect of SGLT2 inhibition on PTH, fibroblast growth factor 23 and 25(OH) vitamin D – **De Jong M. A.**
- PP-6 Myocardial flow reserve assessed by Cardiac 82Rb PET/CT is associated with albumin excretion in patients with type 1 diabetes – **Zobel E. H.**

Parallel Poster Session 2 – Experimental aspects in diabetic kidney disease

Chair: Aldo Tufro

- PP-7 Gastric bypass vs. ‘Medical Bypass’ – Impact on experimental diabetic kidney disease – **Nair M.**
- PP-8 MicroRNA expression changes in podocyte insulin resistance: A new therapeutic target for diabetic nephropathy? – **Wonnacot A.**
- PP-9 Glomerular Enhancer of Zeste Homolog-2 (EZH2) histone methyltransferase reduces glomerular endothelial glycocalyx during diabetic nephropathy by regulating hyaluronan synthesis – **Sol M.**
- PP-10 Novel surgery-induced rat model of diabetic nephropathy – **Østergaard M. V.**
- PP-11 The adipocytokine neuregulin 4 is reduced in diabetic kidney disease – **Ebert T.**



Draft Program

15.45–16.00 Coffee break and exhibition

16.00–17.15 Session 3 –Clinical interventions in diabetic kidney disease

Chairs: Hiddo Heerspink & Peter Rossing

- OP-11 Effect of Urinary Alkalinization on Urine Uric Acid (UUA) Crystallization in Adults with Type 1 Diabetes (T1D) (Alk-UA Study) - A Pilot Study – **Bjornstad P.**
- OP-12 Prediction of the effect of dapagliflozin on renal and heart failure outcomes based on short-term changes in multiple risk markers – **Idzerda N. M. A.**
- OP-13 Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers – **Dekkers C.**
- OP-14 Empagliflozin (EMPA) and incidence of rapid decline in eGFR in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD): an exploratory analysis from the EMPA-REG OUTCOME® trial – **Hadjadj S.**
- OP-15 Effect of dapagliflozin on albuminuria and renin-angiotensin system when added to renin-angiotensin blockade in patients with type 2 diabetes and nephropathy – **Eickhoff M.**

17.15–18.00 Annual General Meeting of the EDNSG

18.30 Groningen canal tour or Museum guided tour

19.30 Welcome reception at the Museum

This reception is offered to you by the University of Groningen, the Municipality of Groningen and the Province of Groningen

20.00 Working Dinner at the Museum

Saturday, May 19th 2018

09.00–09.45 Invited lecture 2 *Chair: Samy Hadjadj*

Novel lipid targets for therapy in DKD

Alessia Fornoni

09.45–10.45 Session 4 – Clinical diabetic kidney disease

Chairs: Lena Thorn & Janaka Karalliedde

- OP-16 Glycosuria response to hyperglycaemia and risk for diabetic nephropathy and related events in patients with type 1 diabetes – **Velho G.**
- OP-17 Estimated Glucose Disposal Rate, Diabetic Kidney Disease and Long-term Survival in Individuals with Type 2 Diabetes Mellitus: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study – **Solini A.**



Draft Program

- OP-18 Association of early-onset type 2 diabetes with high risk for chronic kidney disease progression - a perspective cohort study – **Liu J-J.**
- OP-19 Changes in albuminuria but not glomerular filtration rate associate with early changes in kidney structure in type 2 diabetes – **Looker H. C.**

10.45–11.15 Coffee break and exhibition

11.15–12.15 Session 5 – Novel techniques to study pathophysiology of diabetic kidney disease
Chairs: Catherine Godson & Markku Lehto

- OP-20 Single-cell transcriptome profiling of kidney glomeruli in health and diabetes – **He B.**
- OP-21 Utilisation of stem cell technology FOR the generation of patient-derived human kidney organoids – **Uusi-Rauva K.**
- OP-22 Urinary extracellular vesicles in diabetic kidney disease: validation of preferable preparative techniques – **Barreiro K.**
- OP-23 miRNA Expression in Urinary Samples of Patients with Type 2 Diabetes as biomarker for renal fibrosis in Diabetic Nephropathy – **Pontrelli P.**

12.15–13.00 Invited Lecture 3 *Chair: Per Henrik Groop*
Back to the future: From large clinical trials to personalized treatment of diabetic kidney disease
Dick de Zeeuw

13.00–14.00 Lunch

14.00–15.30 Session 6 – Determinants of diabetic kidney disease progression
Chairs: Ronan Roussel & Anna Solini

- OP-24 Are the renal effects of empagliflozin (EMPA) consistent in patients already using medications that alter renal haemodynamics? An exploratory analysis from EMPA-REG OUTCOME® – **Mayer G.**
- OP-25 Determinants of the glomerular hyperfiltration in obese patients with and without diabetes - potential interest of sTNFR1 – **Barbieux P.**
- OP-26 Plasma concentrations of betaine, choline, carnitine and TMAO and progression to end-stage renal disease in patients with type 2 diabetes: the SURDIAGENE cohort – **Croyal M.**
- OP-27 Apolipoprotein C3 in diabetic nephropathy in type 1 diabetes and its role in cardiovascular disease – **Stechemesser L.**
- OP-28 Circulating inflammatory proteins are associated with ESRD in Southwestern American Indians with type 2 diabetes – **Saulnier P-J.**
- OP-29 Collagen type III degradation is associated with deterioration of kidney function in patients with type 2 diabetes with microalbuminuria – **Frimodt-Møller M.**

15.30–16.00 Closing session

Best Communications Prizes
Closing Remarks and coffee to go